BMS – Talk Bio

Bristol Myers Squibb (BMS), Celgene Acquisition, $6.4 Billion Lawsuit, Contingent Value Rights (CVR), Federal Judge Ruling, Pharmaceutical Industry, Legal Dispute

Prime Medicine Partners with Bristol Myers Squibb in $3.5B Cell Therapy Deal, Narrows Pipeline Focus

7 months ago talkbio0Tagged BMS, Burning Mouth Syndrome, Cell Therapy, Edit, ex vivo, Gene Modification, Ifosfamide/Methotrexate/Procarbazine protocol, PASSIGE, pipeline, Prime Medicine, Reprioritization, squibb, strategic collaboration, Technology

Prime Medicine, Bristol Myers Squibb (BMS), Cell Therapy, Gene Editing, Prime Editing, PASSIGE Technology, Ex Vivo T-Cell Therapies, Pipeline Reprioritization, Strategic Collaboration

FDA to Reassess Use of PD-1 Inhibitors in Stomach Cancer, Seeking Expert Input on Merck, BMS, and BeiGene Medications

8 months ago talkbio0Tagged BeiGene, BMS, Burning Mouth Syndrome, Gene Expression, inhibitors, Merck, Oncologic, PD-L1, PD-L1, PDCD1 gene, United States Food and Drug Administration

FDA, PD-1 inhibitors, stomach cancer, Merck, BMS, BeiGene, Oncologic Drugs Advisory Committee, PD-L1 expression

Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

11 months ago talkbio0Tagged AstraZeneca, Bio, BMS, Breyanzi, Burning Mouth Syndrome, Celcuity, Compugen, K-ras Oncogene, luteolin-7-O-diglucuronide 4'-O-glucuronosyltransferase activity, milestone payments, Nordisk, Novartis, Nxera, United States Food and Drug Administration

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis

Cytokinetics’ Phase III Trials Show Promise in Challenging Cardiomyopathy Treatment Dominated by BMS

12 months ago talkbio0Tagged BMS, Cardiomyopathies, Cardiovascular Diseases, Clinical Data, Cytokinetics, Heart failure, mecarbil, Myocardium, myosin inhibitors, omecamtiv, Phase 3 Clinical Trials

Cytokinetics, Phase III trials, cardiomyopathy, Bristol-Myers Squibb (BMS), heart failure treatment, myosin inhibitors, omecamtiv mecarbil, clinical data, heart muscle contraction, cardiovascular disease.

Pathios Secures $25M in Funding from BMS to Advance GPR65 Checkpoint Inhibitor Development

1 year ago1 year ago talkbio0Tagged Biotechnology, BMS, Bristol Myers Squibb, checkpoint inhibitor, Drug Development, GPR65 gene, Immunotherapy for cancer, Investments, Pathios

Pathios, Bristol-Myers Squibb (BMS), funding, GPR65, checkpoint inhibitor, cancer immunotherapy, drug development, biotechnology, investment.